3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Neoplasms
7
Brain Neoplasms
4
Pain
2
Neuralgia
2
Glioma
2
Depression
2
Visceral Pain
1
Recurrence
1
Rectal Neoplasms
1
Pituitary Neoplasms
1
Pancreatic Neoplasms
1
Neurologic Manifestations
1
Lymphoma, Follicular
1
Language Disorders
1
Headache
1
Glioblastoma
1
Fatigue
1
Depressive Disorder, Major
1
Cognitive Dysfunction
1
Carcinoma, Renal Cell
1
Cancer Survivor
1
Anxiety Disorders
1
Agnosia
1
Acromegaly
1
Interventions
Cyclophosphamide
115
Dexamethasone
70
fludarabine phosphate
57
Cytarabine
56
fludarabine
52
Rituximab
51
Peripheral Blood Stem Cell Transplantation
40
Etoposide
40
Gemcitabine
39
Lenalidomide
38
pembrolizumab
33
Radiotherapy
33
Busulfan
33
Filgrastim
32
Carboplatin
31
Methotrexate
30
Cyclosporine
29
Cisplatin
29
Bortezomib
29
Mycophenolic Acid
28
Melphalan
28
venetoclax
27
Paclitaxel
26
Whole-Body Irradiation
24
Antilymphocyte Serum
23
Temozolomide
22
Granulocyte Colony-Stimulating Factor
20
Calcium Dobesilate
20
Bevacizumab
20
Tacrolimus
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Recurrence
×
Transcranial Magnetic Stimulation
×
Clear all
NCT01718730
2019-10-22
Cortical Excitability and Inhibition in MDD
Mayo Clinic
Completed
23 enrolled